BIOMAT Database Logo BIOMAT Database Logo

[Glycosyltransferases as substrates for Alzheimer's beta-secretase]. 2004

Shinobu Kitazume, and Norihiro Kotani, and Hiroshi Nakato, and Takaomi Saido, and Yasuhiro Hashimoto

UI MeSH Term Description Entries
D010450 Endopeptidases A subclass of PEPTIDE HYDROLASES that catalyze the internal cleavage of PEPTIDES or PROTEINS. Endopeptidase,Peptide Peptidohydrolases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000094802 beta-D-Galactoside alpha 2-6-Sialyltransferase Sialyltransferases that catalyze the transfer of N-ACETYLNEURAMINIC ACID from CYTIDINE MONOPHOSPHATE N-ACETYLNEURAMINIC ACID to the 6-OH of the GALACTOSE residue of N-GLYCANS. CMP-Acetylneuraminate Galactoside (alpha 2-6)-Sialyltransferase,CMP-N-Acetylneuraminate-Galactosylglycoprotein Sialyltransferase ST6GAL,CMP-N-Acetylneuraminate-beta-Galactoside alpha-2,6-Sialyltransferase,CMP-N-Acetylneuraminic Acid-Lactose Sialytransferase,CMP-NeuAc-Galactoside (alpha 2-6)-Sialyltransferase,CMP-Sialic Acid-N-Acetyllactosaminide alpha (2-6)-Sialyltransferase,Gal-1-4-GlcNAc alpha(2-6)-Sialyltransferase,alpha 2-6-Sialyltransferase,alpha2,6(N) Sialyltransferase,alpha6-Sialyltransferase,beta-D-Galactoside alpha-2-6-Sialyltransferase,beta-Galactoside alpha2,6-Sialyltransferase,beta-Galactosyl(1-4)N-Acetylglucosaminide alpha(2-6)-Sialyltransferase,Gal-GlcNAc(2-6)-sialyltransferase,SIAT-1,ST6(N),ST6Gal I,ST6Gal-1,2-6-Sialyltransferase, alpha,2-6-Sialyltransferase, beta-D-Galactoside alpha,Acid-Lactose Sialytransferase, CMP-N-Acetylneuraminic,CMP N Acetylneuraminate Galactosylglycoprotein Sialyltransferase ST6GAL,CMP N Acetylneuraminate beta Galactoside alpha 2,6 Sialyltransferase,CMP N Acetylneuraminic Acid Lactose Sialytransferase,SIAT 1,ST6GAL, CMP-N-Acetylneuraminate-Galactosylglycoprotein Sialyltransferase,ST6Gal 1,Sialyltransferase ST6GAL, CMP-N-Acetylneuraminate-Galactosylglycoprotein,Sialytransferase, CMP-N-Acetylneuraminic Acid-Lactose,alpha 2 6 Sialyltransferase,alpha 2-6-Sialyltransferase, beta-D-Galactoside,alpha-2,6-Sialyltransferase, CMP-N-Acetylneuraminate-beta-Galactoside,alpha-2-6-Sialyltransferase, beta-D-Galactoside,alpha2,6-Sialyltransferase, beta-Galactoside,alpha6 Sialyltransferase,beta D Galactoside alpha 2 6 Sialyltransferase,beta Galactoside alpha2,6 Sialyltransferase
D000544 Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57) Acute Confusional Senile Dementia,Alzheimer's Diseases,Dementia, Alzheimer Type,Dementia, Senile,Presenile Alzheimer Dementia,Senile Dementia, Alzheimer Type,Alzheimer Dementia,Alzheimer Disease, Early Onset,Alzheimer Disease, Late Onset,Alzheimer Sclerosis,Alzheimer Syndrome,Alzheimer Type Senile Dementia,Alzheimer's Disease,Alzheimer's Disease, Focal Onset,Alzheimer-Type Dementia (ATD),Dementia, Presenile,Dementia, Primary Senile Degenerative,Early Onset Alzheimer Disease,Familial Alzheimer Disease (FAD),Focal Onset Alzheimer's Disease,Late Onset Alzheimer Disease,Primary Senile Degenerative Dementia,Senile Dementia, Acute Confusional,Alzheimer Dementias,Alzheimer Disease, Familial (FAD),Alzheimer Diseases,Alzheimer Type Dementia,Alzheimer Type Dementia (ATD),Alzheimers Diseases,Dementia, Alzheimer,Dementia, Alzheimer-Type (ATD),Familial Alzheimer Diseases (FAD),Presenile Dementia,Sclerosis, Alzheimer,Senile Dementia
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012799 Sialyltransferases A group of enzymes with the general activity CMP-N-acetylneuraminate:acceptor N-acetylneuraminyl transferase. They catalyze the transfer of N-ACETYLNEURAMINIC ACID from CMP-N-ACETYLNEURAMINIC ACID to an acceptor, which is usually the terminal sugar residue of an oligosaccharide, a glycoprotein, or a glycolipid. Glycoprotein Sialyltransferases,Glycosyltransferase Family 29,Sialyltransferase,Ectosialyltransferase,Glycoprotein Sialyltransferase,Sialyltransferase, Glycoprotein,Sialyltransferases, Glycoprotein
D013379 Substrate Specificity A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts. Specificities, Substrate,Specificity, Substrate,Substrate Specificities
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D016282 Aspartic Acid Endopeptidases A sub-subclass of endopeptidases that depend on an ASPARTIC ACID residue for their activity. Aspartic Endopeptidases,Aspartyl Endopeptidases,Acid Endopeptidases, Aspartic,Endopeptidases, Aspartic Acid,Endopeptidases, Aspartyl
D053829 Amyloid Precursor Protein Secretases Endopeptidases that are specific for AMYLOID PROTEIN PRECURSOR. Three secretase subtypes referred to as alpha, beta, and gamma have been identified based upon the region of amyloid protein precursor they cleave. APP Secretase,Amyloid Precursor Protein Secretase,Secretase,Secretases,alpha-Secretase,beta-Secretase,gamma-Secretase,Secretase, APP,alpha Secretase,beta Secretase,gamma Secretase

Related Publications

Shinobu Kitazume, and Norihiro Kotani, and Hiroshi Nakato, and Takaomi Saido, and Yasuhiro Hashimoto
beta-Secretase as a therapeutic target for Alzheimer's disease.
July 2008, Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics,
Shinobu Kitazume, and Norihiro Kotani, and Hiroshi Nakato, and Takaomi Saido, and Yasuhiro Hashimoto
Beta-secretase (BACE) as a drug target for Alzheimer's disease.
December 2002, Advanced drug delivery reviews,
Shinobu Kitazume, and Norihiro Kotani, and Hiroshi Nakato, and Takaomi Saido, and Yasuhiro Hashimoto
Beta-secretase as a target for the treatment of Alzheimer's disease.
November 2002, Journal of neuroscience research,
Shinobu Kitazume, and Norihiro Kotani, and Hiroshi Nakato, and Takaomi Saido, and Yasuhiro Hashimoto
Repression of Alzheimer's beta-secretase.
November 2013, Aging,
Shinobu Kitazume, and Norihiro Kotani, and Hiroshi Nakato, and Takaomi Saido, and Yasuhiro Hashimoto
Alzheimer's beta-secretase cleaves a glycosyltransferase as a physiological substrate.
January 2004, Glycoconjugate journal,
Shinobu Kitazume, and Norihiro Kotani, and Hiroshi Nakato, and Takaomi Saido, and Yasuhiro Hashimoto
Human beta-secretase and Alzheimer's disease.
June 2001, Expert opinion on therapeutic targets,
Shinobu Kitazume, and Norihiro Kotani, and Hiroshi Nakato, and Takaomi Saido, and Yasuhiro Hashimoto
Secretase as a target for Alzheimer's disease.
April 2002, Current topics in medicinal chemistry,
Shinobu Kitazume, and Norihiro Kotani, and Hiroshi Nakato, and Takaomi Saido, and Yasuhiro Hashimoto
Engineered heparins: novel beta-secretase inhibitors as potential Alzheimer's disease therapeutics.
January 2008, Neuro-degenerative diseases,
Shinobu Kitazume, and Norihiro Kotani, and Hiroshi Nakato, and Takaomi Saido, and Yasuhiro Hashimoto
Adducts of uridine and glycals as potential substrates for glycosyltransferases.
October 2007, Bioorganic chemistry,
Shinobu Kitazume, and Norihiro Kotani, and Hiroshi Nakato, and Takaomi Saido, and Yasuhiro Hashimoto
Chemoenzymatic synthesis of biotinylated nucleotide sugars as substrates for glycosyltransferases.
December 2001, Chembiochem : a European journal of chemical biology,
Copied contents to your clipboard!